ठळक बातम्या
Flash News
‘A good teacher will never leave students halfway…’: Byju’s founder Raveendran on why he didn’t agree to shut down businesses
New Foxconn unit in India to begin shipping iPhones soon amidst Donald Trump’s call for Apple to shift production to US
IPO-bound Shiprocket launches India’s first AI-integrated MCP server to drive autonomous eCommerce
India to lead in shaping 6G technology regulations, says Jyotiraditya Scindia
RITES eyes revenue growth through export focus, quality assurance & business diversification: CMD
Dr Reddy’s receives two USFDA observations for New York API facility
European chemical industry woes present market opportunity for India: Report
Gensol CFO Jabirmahendi Mohammedraza Aga resigns amid mounting crisis and regulatory heat
DPIIT partners with GEAPP to boost climate-tech startups with funding, mentorship
US Federal Reserve to cut workforce by 10% over next few years
Saturday, May 17, 2025
Dr. Reddy’s Laboratories faced USFDA scrutiny at its New York API facility, receiving a Form 483 with two observations after a GMP inspection concluded on May 16, 2025. The company will address these concerns within the given timeframe.